PT - JOURNAL ARTICLE AU - Basnet, Lila Bahadur AU - Thapa, Pomawati AU - Bastola, Anup AU - Khanal, Narendra AU - Panta, Niranjan AU - Thapaliya, Sabin AU - Kleine Bingham, Melissa Beth AU - Shrestha, Saugat AU - Adhikari, Shital AU - Khadka, Sudesha AU - Shrestha, Priyanka AU - Paudel, Sadhana AU - Devapitchai, Kamaraj Arulmozhi TI - Prevalence and clinical presentations of post-COVID-19 conditions in Nepal AID - 10.1101/2024.04.17.24305977 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.17.24305977 4099 - http://medrxiv.org/content/early/2024/04/19/2024.04.17.24305977.short 4100 - http://medrxiv.org/content/early/2024/04/19/2024.04.17.24305977.full AB - Introduction The COVID-19 pandemic affected millions worldwide. While the major focus was on diagnosis and treatment of the acute phase of the disease, many individuals experienced long-term health even after recovery. These post-COVID-19 conditions encompass a broad range of physical, psychological, and cognitive symptoms that persist beyond the acute phase of the illness. The aim of this study was to find the prevalence and reported presentations of post-COVID-19 conditions in Nepal.Method This is a retrospective cross-sectional study using structured questionnaire to collect hospital-based data available in the record of Curative Service Division, Department of Health Services of Nepal from October 2021 to September 2022. A total of 6151 cases were recorded in the study. Descriptive analysis was done for demographic and symptoms variable. Association of variables to post-COVID-19 condition are shown using univariate and multivariate logistic regression.Results Among 6151 respondents (62.25% males), more than half (59.03%) had at least one symptom after recovery from acute COVID-19. The most common symptoms were anxiety (28.5%), loss of appetite (25.3%), shortness of breath (24.13%), fatigue (23.24%), depressed mood (18.79%), muscle ache (17.59%), chest pain (16.81%), headache (14.78%), and palpitation (13%). Multivariate analysis showed increased odds of post-COVID-19 conditions in smokers (adjusted OR [aOR] 1.53), those with chronic lung disease (aOR 1.71), neurological disorder (aOR 2.43) and those with use of supplementary oxygen during acute illness of COVID-19 (aOR 3.37).Conclusion The prevalence of post-COVID-19 symptoms among the study population is found to be high. The main symptoms from our study and similar studies are anxiety, fatigue, loss of appetite, shortness of breath, muscle pain, headaches. Patients with smoking, hypoxia during acute illness and presence of chronic lung disease and neurological disorder had higher odds of getting post-COVID-19 conditions. Citing the findings, health system should focus upon the management and recording of such conditions for further evidence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from National Health Research Council Ethical Review Board. Permission to access data was obtained from the Curative Service Division. Nepal Health Research Council (NHRC) Ref. No.: 1365I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying the results presented in the study are available from Curative Service Division, Department of Health Services (csd.teku{at}gmail.com).